Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain

In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater.

The genesis of Elemental IV didn’t occur in a sterile laboratory, but in a tense meeting room filled with exhausted regional nurses and midwives. Paes was there to facilitate a strategy session on critical supply shortages. What she heard shocked her.

“I remember sitting in the room… hearing about critical shortages, particularly saline,” Paes recalls. “I thought, what a strange problem that there are shortages in this space.”

That curiosity sparked a deep dive into Australia’s medical supply chain, revealing a structural fragility that most Australians and many investors have yet to grasp. Despite our world-class healthcare system, Australia imports over 80% of its essential sterile fluids from a single foreign supplier.

In clinical terms, sterile saline and water for injection are the “connective tissue” of medicine. They are used for everything from basic hydration and wound irrigation to serving as the essential base for compounding complex therapies and emergency medicines.

Currently, Australia operates under a functional monopoly. When global supply chains fracture—as they did during COVID-19 or natural disasters—the “just-in-time” delivery model collapses.

“It wasn’t a problem until it was a problem,” Paes says of the post-COVID realisation. “There is a real supply chain risk and real issues around being able to reliably source products overseas. This has really turned heads in terms of the need for a sovereign supplier.”

Elemental IV isn’t just another distributor but a manufacturing play. The company is building Australia’s first modular, GMP-certified facility for sterile fluids, slated for South Australia with state government support.

By utilising a modular approach, Elemental IV can scale rapidly to meet the “Standard of Care” requirements while maintaining the rigorous Therapeutic Goods Administration (TGA) approvals necessary for sterile injectables.

The strategy is surgical rather than expansive. “We don’t want to compete with the big players,” Paes explains. “We want to supplement the market and tackle the critical-to-low supply shortages—the things that currently have no local supplier.”

From an investment perspective, Elemental IV represents a pivot from the high-burn, high-risk biotech model to a defensive, long-term infrastructure play.

While drug developers chase a binary “pass/fail” result in clinical trials, Elemental IV is building an institutional asset with a built-in customer base: every hospital, defense unit, and aged care facility in the country.

The Operational Edge:

The company is currently moving through its regulatory and construction milestones. For investors, the “value inflection” lies in the transition from a capital-intensive build phase to a revenue-generating sovereign asset.

As geopolitical tensions and climate-related shipping disruptions become the “new normal,” the valuation of domestic manufacturing capabilities is undergoing a significant rerate. In the US and Europe, similar sovereign “resilience” plays are fetching premiums from institutional funds.

Paes is candid about the company’s profile. “This is more of a ‘Hummer’ in that it will be here forever,” she says. “If you want to be a strategic investor, you are becoming part of something structural and institutional.”

For those seeking exposure to the life sciences sector without the traditional “binary” drug-trial risk, Elemental IV offers a rare combination: a noble mission to secure Australian healthcare and a pragmatic, infrastructure-backed path to commercial returns.

In a sector defined by “moonshots,” Elemental IV is betting on the most essential element of all: the ability to keep the lights on—and the drips running—at the patient’s bedside.